These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 22499411)

  • 1. Possible correlation of sirolimus plasma concentration with sinusoidal obstructive syndrome of the liver in patients undergoing myeloablative allogeneic hematopoietic cell transplantation.
    Kiel PJ; Vargo CA; Patel GP; Rosenbeck LL; Srivastava S
    Pharmacotherapy; 2012 May; 32(5):441-5. PubMed ID: 22499411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
    Rosenbeck LL; Kiel PJ; Kalsekar I; Vargo C; Baute J; Sullivan CK; Wood L; Abdelqader S; Schwartz J; Srivastava S; Abonour R; Robertson MJ; Nelson RP; Cornetta K; Fausel CA; Farag SS
    Biol Blood Marrow Transplant; 2011 Jun; 17(6):916-22. PubMed ID: 20932925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
    Cutler C; Kim HT; Hochberg E; Ho V; Alyea E; Lee SJ; Fisher DC; Miklos D; Levin J; Sonis S; Soiffer RJ; Antin JH
    Biol Blood Marrow Transplant; 2004 May; 10(5):328-36. PubMed ID: 15111932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial.
    Platzbecker U; von Bonin M; Goekkurt E; Radke J; Binder M; Kiani A; Stoehlmacher J; Schetelig J; Thiede C; Ehninger G; Bornhäuser M
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):101-8. PubMed ID: 19135948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens.
    Cutler C; Li S; Kim HT; Laglenne P; Szeto KC; Hoffmeister L; Harrison MJ; Ho V; Alyea E; Lee SJ; Soiffer R; Sonis S; Antin JH
    Biol Blood Marrow Transplant; 2005 May; 11(5):383-8. PubMed ID: 15846292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation.
    Cutler C; Henry NL; Magee C; Li S; Kim HT; Alyea E; Ho V; Lee SJ; Soiffer R; Antin JH
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):551-7. PubMed ID: 15983555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Sirolimus levels between days 11 and 20 after allogeneic stem cell transplantation on the risk of hepatic sinusoidal obstruction syndrome.
    Agrawal V; Ranganath P; Ervin KD; Schmidt CA; Cox EA; Nelson RP; Schwartz JE; Zaid MA; Abonour R; Robertson MJ; Brinda BJ; Griffin SP; Thakrar TC; Farag SS
    Bone Marrow Transplant; 2021 Jan; 56(1):121-128. PubMed ID: 32623447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lowered-intensity preparative regimen for allogeneic stem cell transplantation delays acute graft-versus-host disease but does not improve outcome for advanced hematologic malignancy.
    Levine JE; Uberti JP; Ayash L; Reynolds C; Ferrara JL; Silver SM; Braun T; Yanik G; Hutchinson R; Ratanatharathorn V
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):189-97. PubMed ID: 12652470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant.
    Ceberio I; Devlin SM; Sauter C; Barker JN; Castro-Malaspina H; Giralt S; Ponce DM; Lechner L; Maloy MA; Goldberg JD; Perales MA
    Leuk Lymphoma; 2015 Mar; 56(3):663-70. PubMed ID: 24913499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of early posttransplantation tacrolimus concentration on the development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation from unrelated donors.
    Mori T; Kato J; Shimizu T; Aisa Y; Nakazato T; Yamane A; Ono Y; Kunimoto H; Okamoto S
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):229-34. PubMed ID: 21708109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus and tacrolimus as immune prophylaxis compared to cyclosporine with or without methotrexate in patients undergoing allogeneic haematopoietic stem cell transplantation for non-malignant disorders.
    Ringdén O; Remberger M; Dahllöf G; Garming-Legert K; Karlsson H; Svenberg P; Uhlin M; Uzunel M; Mattsson J
    Eur J Haematol; 2011 Dec; 87(6):503-9. PubMed ID: 22974354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic veno-occlusive disease following sirolimus-based immune suppression.
    Khimani F; McDonald GB; Shulman HM; Betts B; Locke F; Fernandez H; Anasetti C; Pidala J
    Bone Marrow Transplant; 2019 Jan; 54(1):85-89. PubMed ID: 29895929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Absorption, Distribution, Metabolism, and Excretion Genomic Variants on Tacrolimus/Sirolimus Blood Levels and Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
    Khaled SK; Palmer JM; Herzog J; Stiller T; Tsai NC; Senitzer D; Liu X; Thomas SH; Shayani S; Weitzel J; Forman SJ; Nakamura R
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):268-276. PubMed ID: 26325438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation.
    Cutler C; Stevenson K; Kim HT; Richardson P; Ho VT; Linden E; Revta C; Ebert R; Warren D; Choi S; Koreth J; Armand P; Alyea E; Carter S; Horowitz M; Antin JH; Soiffer R
    Blood; 2008 Dec; 112(12):4425-31. PubMed ID: 18776081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Second transplantation for graft failure after allogeneic hematopoietic stem cell transplantation--a retrospective survey by Kanto Study Group for Cell Therapy].
    Hagihara M; Kanamori H; Sakai M; Mori T; Nakaseko C; Aotsuka N; Uehara T; Sakura T; Yoshiba F; Kawai N; Tanaka M; Fujisawa S; Ohwada C; Wakita H; Yokota A; Kawamura T; Maruta A; Sakamaki H; Okamoto S;
    Rinsho Ketsueki; 2010 Jun; 51(6):390-7. PubMed ID: 20622484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update.
    Cutler C; Antin JH
    Curr Opin Hematol; 2010 Nov; 17(6):500-4. PubMed ID: 20717025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
    Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
    Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged sirolimus administration after allogeneic hematopoietic cell transplantation is associated with decreased risk for moderate-severe chronic graft-versus-host disease.
    Pidala J; Kim J; Alsina M; Ayala E; Betts BC; Fernandez HF; Field T; Jim H; Kharfan-Dabaja MA; Locke FL; Mishra A; Nishihori T; Ochoa-Bayona L; Perez L; Riches M; Anasetti C
    Haematologica; 2015 Jul; 100(7):970-7. PubMed ID: 25840599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.